SGLT2-INHIBITORER TIL BEHANDLINGEN AF METABOLISKE LIDELSER I KATTEDYR

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidos...

Full description

Saved in:
Bibliographic Details
Main Authors HENNINGS, Leah Jeanette, REICHE, Dania Birte, TRAAS, Anne M, HAAG-DIERGARTEN, Silke, KLEY, Saskia
Format Patent
LanguageDanish
Published 03.05.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.
Bibliography:Application Number: DK20140820808T